NEUMORA THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $59.00K, a 97.78% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $1.76M, a 16.21% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $2.65M, a 556.93% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $1.84M, a 206.48% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $275.00K, a 96.32% decline from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $7.48M, a 161.97% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $2.86M, a 366.67% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $612.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $275.00K 10-K · filed 2026-03-30 | |
| 2025-06-30 | $59.00K 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $7.48M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $1.76M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $2.65M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $1.84M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.86M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $1.51M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $404.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $602.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $612.00K 10-K · filed 2025-03-03 | |
| 2022-09-30 | $148.00K 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $258.00K 10-Q · filed 2023-11-01 | |
| 2022-03-31 | $164.00K 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |